JP5177444B2 - Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト - Google Patents

Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト Download PDF

Info

Publication number
JP5177444B2
JP5177444B2 JP2009244448A JP2009244448A JP5177444B2 JP 5177444 B2 JP5177444 B2 JP 5177444B2 JP 2009244448 A JP2009244448 A JP 2009244448A JP 2009244448 A JP2009244448 A JP 2009244448A JP 5177444 B2 JP5177444 B2 JP 5177444B2
Authority
JP
Japan
Prior art keywords
seq
antibody
human
antibodies
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2009244448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010077133A (ja
Inventor
ロバート・エス・エイムス
エドワード・ロバート・アペルバウム
アーウィン・エム・チェイケン
リチャード・エム・クック
ミッチェル・スチュアート・グロス
スティーブン・ダドレイ・ホルムス
リネット・ジェーン・マクミラン
ティモシー・ウェイン・セイセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
GlaxoSmithKline LLC
Original Assignee
SmithKline Beecham Ltd
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, GlaxoSmithKline LLC filed Critical SmithKline Beecham Ltd
Publication of JP2010077133A publication Critical patent/JP2010077133A/ja
Application granted granted Critical
Publication of JP5177444B2 publication Critical patent/JP5177444B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009244448A 1994-12-23 2009-10-23 Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト Expired - Lifetime JP5177444B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/363,131 1994-12-23
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 1995-06-06
US08/467,420 1995-06-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007269236A Division JP2008029355A (ja) 1994-12-23 2007-10-16 Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012220614A Division JP2013091636A (ja) 1994-12-23 2012-10-02 Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト

Publications (2)

Publication Number Publication Date
JP2010077133A JP2010077133A (ja) 2010-04-08
JP5177444B2 true JP5177444B2 (ja) 2013-04-03

Family

ID=23428947

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009244448A Expired - Lifetime JP5177444B2 (ja) 1994-12-23 2009-10-23 Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
JP2012220614A Pending JP2013091636A (ja) 1994-12-23 2012-10-02 Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012220614A Pending JP2013091636A (ja) 1994-12-23 2012-10-02 Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト

Country Status (11)

Country Link
US (5) US5693323A (en:Method)
EP (1) EP1749840A3 (en:Method)
JP (2) JP5177444B2 (en:Method)
KR (1) KR100511544B1 (en:Method)
CN (1) CN101353381A (en:Method)
CY (2) CY2592B2 (en:Method)
FR (1) FR15C0089I2 (en:Method)
HU (1) HUS1500070I1 (en:Method)
NO (1) NO2018035I1 (en:Method)
PT (1) PT800536E (en:Method)
ZA (1) ZA9510965B (en:Method)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ES2277336T3 (es) * 1994-12-23 2007-07-01 Smithkline Beecham Corporation Antagonistas de il-5 recombinantes utiles en el tratamiento de enfermadades mediadas por il-5.
FR2783326B1 (fr) * 1998-09-10 2000-12-01 Immunotech Sa Procede de detection ou de quantification des basophiles et des eosinophiles
AR025984A1 (es) * 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US7314572B1 (en) 2006-02-14 2008-01-01 Meurer Research, Inc. Methods of and apparatus for low-angle-tray settling with multi-zone configuration
US7718076B1 (en) 2006-02-14 2010-05-18 Charles Lonnie Meurer Methods of and common gantry drive for single-pass cleaning of multiple stages of a material separation and removal system
US7780015B1 (en) 2006-08-24 2010-08-24 Meurer Research, Inc. Methods of and sludge collector with adjacent opposed oppositely-moving blades for moving sludge in a basin
JP2010526088A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
US7560035B1 (en) 2007-06-22 2009-07-14 Charles Lonnie Meurer Overhead trough with constant trough flow velocity configuration and methods of regulating trough flow velocity
CA2719786A1 (en) 2008-03-28 2009-10-01 Glaxosmithkline Llc Methods of treatment
BR112013016235B1 (pt) 2010-12-22 2020-03-31 Cephalon Australia Pty Ltd Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN108137683A (zh) 2015-08-24 2018-06-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
MX2019007642A (es) * 2016-12-23 2019-09-09 Cephalon Inc Anticuerpos anti-il-5.
US20190389958A1 (en) * 2017-01-31 2019-12-26 Msm Protein Technologies, Inc. Anti-cxcr4 antibodies
CN110494152B (zh) * 2017-02-10 2024-04-09 梅约医学教育与研究基金会 短trail抗体及使用方法
EA201992802A1 (ru) * 2017-05-26 2020-07-10 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Биофармацевтические композиции и связанные с ними способы
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
MY201928A (en) 2017-09-29 2024-03-24 Shanghai hengrui pharmaceutical co ltd Il-5 antibody, antigen binding fragment thereof, and medical application therefor
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
CN113366016B (zh) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
CN113769081A (zh) * 2020-06-10 2021-12-10 三生国健药业（上海）股份有限公司 一种稳定的高浓度抗人il-5单克隆抗体液体制剂
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
DE68911653T2 (de) * 1988-11-03 1994-04-07 Schering Corp Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie.
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CZ287296B6 (en) * 1992-01-23 2000-10-11 Merck Patent Gmbh Antibody construct and structural kit for selective preparation thereof
HUT67943A (en) * 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) * 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
WO1995014040A1 (en) 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
ES2277336T3 (es) * 1994-12-23 2007-07-01 Smithkline Beecham Corporation Antagonistas de il-5 recombinantes utiles en el tratamiento de enfermadades mediadas por il-5.
WO2001012646A1 (en) 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies

Also Published As

Publication number Publication date
US20030059429A1 (en) 2003-03-27
US5683892A (en) 1997-11-04
HUS1500070I1 (hu) 2017-07-28
CY2592B2 (en) 2009-11-04
CN101353381A (zh) 2009-01-28
US20040156850A1 (en) 2004-08-12
US6946130B2 (en) 2005-09-20
CY2015056I2 (el) 2016-06-22
EP1749840A2 (en) 2007-02-07
NO2018035I1 (no) 2018-10-04
JP2013091636A (ja) 2013-05-16
FR15C0089I1 (en:Method) 2016-12-02
EP1749840A3 (en) 2008-10-15
ZA9510965B (en) 1996-09-16
FR15C0089I2 (fr) 2016-07-01
JP2010077133A (ja) 2010-04-08
US5851525A (en) 1998-12-22
KR20040101388A (ko) 2004-12-02
KR100511544B1 (ko) 2005-08-31
US5693323A (en) 1997-12-02
PT800536E (pt) 2007-02-28
CY2015056I1 (el) 2016-08-31

Similar Documents

Publication Publication Date Title
JP5177444B2 (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US7982005B2 (en) Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP4954104B2 (ja) Ｉｌ−５介在障害を治療および診断するための改良方法
JP2008029355A (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
EP1163271B1 (en) Recombinant il-18 antibodies and their use
EP0730609B1 (en) Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US7807793B2 (en) Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1995001997A1 (en) RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
KR100509993B1 (ko) Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제
HK1003651B (en) Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
HK1122308A (en) Recombinant il-18 antibodies useful in treatment of il-18 mediated disorders

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121002

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121108

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121225

EXPY Cancellation because of completion of term